StockData

Fortress Biotech vs Viridian Therapeutics, Inc.\DE

FBIO and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FBIO and VRDN compare

Viridian Therapeutics, Inc.\DE is the larger company, worth 51 times as much as Fortress Biotech ($3.4B against $66.9M).

Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus 15.5% for Fortress Biotech).

Fortress Biotech keeps more of each dollar of sales as profit, with a net margin of 163% compared with −544% at Viridian Therapeutics, Inc.\DE.

Fortress Biotech scores higher on the StockData Score (9 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFBIOVRDN
Size and price
Market cap$66.9M$3.4B
Share price$1.82$30.06
Change, 1 year−30.5%4.5%
Change, 5 years−95.7%64.3%
Beta (5Y)0.64−0.13
Employees78252
StockData Score
Total score9 (better)4
Valuation score1 (better)0
Growth score12 (better)
Performance score3 (better)1
Health score4 (better)1
Dividend score00
Valuation
P/S1.0× (better)47.9×
P/B0.4× (better)5.1×
FCF yield–−9.8%
Fair value–$8.47
Margin of safety–−255%
Growth
Revenue growth (TTM)15.5%23220% (better)
Revenue growth, 5Y average6.8%132% (better)
Profitability
Gross margin65.6%–
Operating margin−42.9% (better)−570%
Net margin163% (better)−544%
FCF margin–−471%
Return on equity107% (better)−65.7%
Return on invested capital−261%–
Financial health
Debt / equity0.21–
Interest coverage−3.0× (better)−26.0×
Current ratio3.9616.95 (better)
Altman Z-score−1.792.65 (better)
Piotroski F-score6 (better)4
Dividends and buybacks
Buyback yield–−1.7%
Shareholder yield0.00% (better)−1.7%
Ownership
Held by institutions15.9%120%
Held by insiders31.6%21.8%
Insider net buying, 12 months–$19.6M
Short interest, % of float–19.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.